JPRN-jRCT2080221917未知2 期
PhaseII/III double-blind comparative study of the efficacy and safety of TAK-536CCB when coadministered with hydrochlorothiazide in patients with grade I or II essential hypertensio
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点开始时间: 2012年9月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Grade I or II essential hypertension.
- •- At both Week -2 and Week 0, sitting blood pressure (measured in the examination room) satisfied the following criteria:
- •Systolic blood pressure: >=150 mmHg and <180 mmHg
- •Diastolic blood pressure: >=95 mmHg and <110 mmHg, etc.
排除标准
- •Secondary hypertension, malignant hypertension or grade III hypertension.
- •Significant white-coat hypertension
- •Sleep apnea syndrome requiring treatment
- •Clinically defined hepatic disorder
- •Clinically defined renal disorder
- •Significantly low or high levels of K or Na in body fluids, etc.
研究者
相似试验
进行中（未招募）
不适用
Study comparing 3-weekly carboplatin + paclitaxel with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanced or recurrent cervical carcinoma.Advanced or recurrent cervical carcinomaMedDRA version: 17.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000004864EUCTR2012-004076-19-ESZ Leuven / Belgian Gynaecological Oncology Group120
进行中（未招募）
不适用
A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy na?ve adult subjects. - ING113086treatment- na?ve, HIV infected adultsMedDRA version: 9.1Level: LLTClassification code 10002725EUCTR2009-017950-11-ITViiV Healthcare UK Ltd788
进行中（未招募）
1 期
A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects.EUCTR2009-017950-11-GBViiV Healthcare UK Ltd822
进行中（未招募）
1 期
A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects.HIV-1 infected antiretroviral (ART) - naïve adult subjectsMedDRA version: 12.1Level: LLTClassification code 10008922Term: Chronic infection with HIVEUCTR2009-017950-11-FRViiV Healthcare UK Ltd822
进行中（未招募）
1 期
Study to test a new drug dolutegravir vs. raltegravir for HIVpatients who have never taken HIV medication.HIV-1 infected antiretroviral (ART) - naïve adult subjectsMedDRA version: 14.0Level: LLTClassification code 10008922Term: Chronic infection with HIVSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-017950-11-DEViiV Healthcare UK Ltd788